Needham & Co Upgrades Cepheid (CPHD) to Buy

October 14, 2009 8:58 AM EDT

Needham & Co upgrades Cepheid (Nasdaq: CPHD) from Hold to Buy. Price target $17.

To see more analyst ratings on CPHD Click Here.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.


Related Categories

Upgrades

Stocks Mentioned

CPHD 14.99

+0.28 +1.90%
Volume: 273,718
Track CPHD


Related Entities


Add Your Comment





Follow StreetInsider.com On Twitter